Meet us at the ISN-WCN 23 "World Congress of Nephrology" in Bangkok, 30 March – 2 April 2023!

Logo TauroLock


We have developed catheter lock solutions for patients in various contexts. TauroLock™-U25.000 provides a particularly strong prophylaxis against occlusion, as urokinase serves to break up blood clotting.


Indication and effect

TauroLock™-U25.000 has been approved for instillation in all central-venous access systems. This lock solution reliably prevents the formation of bacterial biofilms within catheters. As a result, patients can avoid infections and maintain a high patency rate.


TauroLock™-U25.000 is based on three active ingredients:


  • taurolidine
  • citrate (4 %)
  • urokinase (25,000 units)


Taurolidine has a broad antimicrobial activity (incl. MRSA and VRE), while citrate works as an anticoagulant. At the same time, urokinase yields a thrombolytic effect.


Before applying TauroLock™-U25.000, dissolve the vial’s content (i.e. 25,000 IU urokinase) with 5 ml of TauroLock™. In-between treatment sessions, TauroLock™-U25.000 is instilled into the vascular access system. Please note that medical staff must check the filling volume of the respective catheter or port system.

Expert recommendations

Taurolidine-based lock solutions such as TauroLock™-U25.000 are recommended in national and international guidelines




TauroLock™-U25.000 is contraindicated:


  • for patients with a known allergy to (cyclo)-taurolidine, citrate or urokinase,
  • or when a patient is currently taking medication with known adverse interaction to citrate, (cyclo)-taurolidine or urokinase.


Prior to the next treatment, TauroLock™-U25.000 must be aspirated and discarded according to the institution’s policy for infectious waste disposal.

Package sizes

You may purchase TauroLock™-U25.000 in vials of 5 ml (single dose, 5 vials per box).

Storage & transport

TauroLock™-U25.000 must be stored at 15 °C to 25 °C. Please note that you must not freeze TauroLock™-U25.000 under any circumstances.

More information about TauroLock™-U25.000

For national guideline recommendations, e.g. DGfN 2019:

“… taurolidine-citrate solutions may be considered … Another option is the intermittent (once weekly) use of urokinase as lock solution (Cat. IB).”

Download AIEOP recommendations for TauroLock™-U25.000 in oncology

Recommendations for locking the CVAD:


  1. The use of normal saline is recommended for locking CVADs. (A I)
    Randomized controlled trials have shown no difference between saline and heparinized solution. Saline is preferable due to the greater handling and the lower risk of side effects compared to heparin, especially in the newborn.
  2. Locking with non-antibiotic antibacterial substances (in particular, 2% taurolidine) has been proven effective in pediatric patients in reducing the risk of infection.
    Data on the pediatric cancer population are still limited. (BI)
  3. The use of thrombolytic substances (urokinase 5000 IU/ml or the tissue activator of plasminogen – rtPA 1 mg/ml) is recommended only in case of occlusion of the catheter lumen due to clots. (A II)

Download DGfN recommendations for TauroLock™-U25.000 in dialysis

“… taurolidine-citrate solutions may be considered … Another option is the intermittent (once weekly) use of urokinase as lock solution.” (Cat. IB)

Download study by Winnicki et al. on taurolidine-based lock solutions in dialysis (2017)

“…Thus, use of taurolidine-based catheter lock solutions containing heparin and urokinase significantly reduced complications related to tunneled hemodialysis catheters when compared to four percent citrate solution and was overall more cost-efficient…”

For personal inquiries, you can also contact us via phone or email.

Our international distributors based in more than 50 countries are happy to offer support ASAP.